TheraRadar
Data updated: May 26, 2026

PERINDOPRIL ERBUMINE

Cardiovascular Approved 2009-11-10

PERINDOPRIL ERBUMINE is indicated for the treatment of Hypertension; Coronary Artery Disease; Myocardial Infarction.

Source: FDA Label • Lupin

How PERINDOPRIL ERBUMINE Works

Perindopril erbumine is a pro-drug for perindoprilat, which lowers blood pressure primarily by inhibiting the angiotensin-converting enzyme (ACE). This inhibition prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. The resulting reduction in angiotensin II levels leads to decreased vasoconstriction and reduced aldosterone secretion, which promotes natriuresis and diuresis. Additionally, perindoprilat inhibits kininase II, the enzyme responsible for breaking down the vasodepressor peptide bradykinin, which may further contribute to its therapeutic effects.

Source: FDA Label
3
Indications
--
Phase 3 Trials
16
Years on Market

Details

Status
Discontinued
First Approved
2009-11-10
Routes
ORAL
Dosage Forms
TABLET

PERINDOPRIL ERBUMINE Approval History

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
51 FDA actions from 2009 to 2024
Jan 2024 SUPPL
Label · Labeling
Jan 2024 SUPPL
Label · Labeling
Nov 2016 SUPPL
Label · Labeling

What PERINDOPRIL ERBUMINE Treats

3 indications

PERINDOPRIL ERBUMINE is approved for 3 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
  • Coronary Artery Disease
  • Myocardial Infarction
Source: FDA Label

PERINDOPRIL ERBUMINE Boxed Warning

FETAL TOXICITY When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.4) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ] . Drugs that a...

PERINDOPRIL ERBUMINE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 16 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to PERINDOPRIL ERBUMINE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CADUET
AMLODIPINE BESYLATE
3 shared
PHARMACIA
ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
2 shared
PH HEALTH
Shared indications:
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
AMLODIPINE BESYLATE
2 shared
Apotex
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01556997 PATH results posted X985400 Ph 3 completed Perindopril Amlodipine for the Treatment of Hypertension
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PERINDOPRIL ERBUMINE FDA Label Details

Indications & Usage

PERINDOPRIL ERBUMINE is indicated for the treatment of Hypertension; Coronary Artery Disease; Myocardial Infarction.

⚠️ BOXED WARNING

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.4) ] . WARNING: ...

Looking for the branded version?

ACEON

Full clinical data, patents, trials, and competitive landscape for perindopril erbumine.

See ACEON

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.